Cargando…
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia...
Autores principales: | Ciardi, Maria Rosa, Zingaropoli, Maria Antonella, Pasculli, Patrizia, Perri, Valentina, Tartaglia, Matteo, Valeri, Serena, Russo, Gianluca, Conte, Antonella, Mastroianni, Claudio Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361089/ https://www.ncbi.nlm.nih.gov/pubmed/32688146 http://dx.doi.org/10.1016/j.jneuroim.2020.577323 |
Ejemplares similares
-
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022) -
Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease
por: Fedele, Giorgio, et al.
Publicado: (2022) -
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2022) -
Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023) -
Major reduction of NKT cells in patients with severe COVID-19 pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)